Clinical Trial Update: Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating lenalidomide in combination with a fixed dose of sorafenib for hepatocellular carcinoma; the study status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Sorafenib (Sorafenib)

Snippet

Sponsor: Indiana University School of Medicine | Conditions: Hepatocellular Carcinoma | Phase 1 | Status: TERMINATED